In March 2016, Gene therapy company Immusoft - also an SBIR involved firm - acquired Discovery Genomics along with its Sleeping Beauty Transposon System designed to deliver genes into cells without using a virus. It was reported that the acquisition will give Immusoft the ability to use Sleeping Beauty with B cells and its own Immune System Programming (ISP) platform to treat diseases. Gene therapy is a technique for adding a corrective gene to prevent or alleviate a disease state. Discovery Genomics, Inc. (DGI) defines itself as a gene therapy company organized around curing disease by delivering therapeutic genes that allow the body to heal itself. Discovery Genomics, Inc. had been a functional genomics company created to discover gene functions, conduct drug target validations, and design therapeutic agents based on genomics information. With a primary focus o gene therapies for blood diseases, he company holds exclusive licenses from the University of Minnesota to develop technologies using a proprietary Morphant(TM) technology and to the use of the Sleeping Beauty Transposon(TM). Both technologies may be used for functional genomics and the discovery of drug targets. The transposon may have applications in gene therapy. Morphant(TM) "knock-downs" are used to suppress and thereby study the functions of particular genes. The Zebrafish model system is a faster and less expensive approach to gene discovery than other vertebrate model systems